• Explore /
  • Poster
  • / Evolution: Phase II study of radionuclide <sup>177</sup>Lu-PSMA-617 therapy versus <sup>177</sup>Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).

Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).

Abstract Poster

Authors

null

Shahneen Sandhu

Peter MacCallum Cancer Centre, Melbourne, Australia

Shahneen Sandhu , Shalini Subramaniam , Michael S Hofman , Martin R. Stockler , Andrew James Martin , Izabella Pokorski , Jeffrey C. Goh , David A. Pattison , Nattakorn Dhiantravan , Craig Gedye , Natalie K. Rutherford , Anthony M. Joshua , Thean Hsiang Tan , Ian D. Kirkwood , Sze Ting Lee , Andrew James Weickhardt , Ramin Alipour , Andrew Nguyen , Ian D. Davis , Louise Emmett

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Cancer Disparities

Clinical Trial Registration Number

NCT05150236

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS271)

DOI

10.1200/JCO.2023.41.6_suppl.TPS271

Abstract #

TPS271

Poster Bd #

P13

Abstract Disclosures

Similar Posters

First Author: Padmanee Sharma

First Author: Karim Boudadi

First Author: Kim N. Chi

First Author: Scott T. Tagawa